Vas Narasimhan, CEO of Novartis AG, has expressed that the Swiss pharma giant is reconsidering its office space usage and may use it for a hybrid work model.
Narasimhan added that this sort of flexibility would allow the company to “access talent pools we would not have been able to access in the past”
This revelation is one that has echoed across various industries as vaccine distribution ramps up and companies plan out their post-pandemic strategies. For many, this means continuing to have both in-office and remote working options as part of their operations.
“We’ll be looking, I think, to adjust our overall footprint and then invest where appropriate,” said Narasimhan.